Recently, Creative Biosciences (Guangzhou) CO., Ltd. (referred to as CreativeBio) was awarded the title of Specialized, Elaborative, Characteristic, and Emerging "Little Giant" (small and medium-sized) Enterprise. This significant honor fully showcases its strong comprehensive strength in the field of in vitro diagnostic reagents in the biopharmaceutical industry, taking the lead in the sector. This title serves as a recognition and commendation of the company's long-standing commitment to independent innovation and the pursuit of excellence. This distinction will undoubtedly boost greater momentum and confidence in company’s future development.

Since its establishment, CreativeBio has been deeply engaged in research, development, production, and testing services of early cancer screening products. The company's flagship product Colosafe^®, a fecal DNA test kit for early detection of colorectal cancer, is highly welcomed in the industry. As of April 30, 2024, its real-world application data has surpassed 830,000 tests. Impressively, on October 21, 2021, Colosafe^® was showcased as an outstanding representative result of the Chinese Ministry of Science and Technology’s key R&D project called “Research on Colorectal Cancer Screening and Intervention Technology in China", at the national 13th Five-Year Plan Scientific and Technological Innovation Achievement Exhibition. As the only early cancer screening product exhibited, it was featured in the "Healthy China" section. This privilege further proves the product's excellence in both innovation and practicality.

CreativeBio has also received numerous accolades at the corporate development level. The company has been recognized as an Innovative Small-Medium Size Enterprise in Guangzhou, and has won the same title in Guangdong Province as Specialized, Elaborative, Characteristic, and Emerging enterprise. These privileges represent high acknowledgement of the company's innovation capabilities, market competitiveness, and growth potential. Additionally, thanks to its outstanding scientific achievements and strength, the company has been awarded the First Prize of the Guangdong Provincial Science and Technology Progress Award in 2018, the Second Prize of the Chinese Medical Science and Technology Award in 2019, and the First Prize of the Ministry of Education's Science and Technology Progress Award in 2020. These outstanding awards are a strong affirmation of the innovation capacity of the entire CreativeBio team.

Behind the numerous honors lies CreativeBio's continuous investment in scientific research and innovation, as well as its strict product quality control. The company boasts a research and development team composed of industry elites who have made several significant breakthroughs in early cancer screening and diagnostic technologies, providing a continuous source of impetus for the ongoing development.

The national-level title of Little Giant Enterprise brings greater responsibility to CreativeBio. Looking ahead, the company will continue to uphold its noble mission of "Human Health, My Mission", increase investment in research and development, and expand international markets. CreativeBio aims to provide precise and efficient early cancer screening and diagnostic products to more patients worldwide, contributing China's strength to building a healthy global community for all.